HIVE eps in a glimpse
Analyst Rating Consensus
20
Ratings
HIVE Price Target
Highest Price Target
$9.00
188.46% Upside
)Mean Price Target
$6.01
92.71% Upside
)Lowest Price Target
$3.50
12.18% Upside
)HIVE Recent Analyst Ratings
Actual EPS vs Estimated EPS
How EPS can be helpful
Understanding the true essence of Earnings Per Share (EPS) for a company can be a complex endeavor. EPS, essentially a measure of a company's profitability on a per-share basis, is often used by investors as a barometer of financial health. However, it's crucial to recognize that EPS can be subject to manipulation through various accounting techniques and management strategies.
HIVE Earnings History
Frequently Asked Questions
Brokerage firms have given HIVE stock an average recommendation of Buy. 20 analysts have given their ratings to HIVE out of which 2 analysts have given strong buy call, 16 analysts have given buy call, 2 analysts rate it hold, 0 analysts advocate strong sell call, and 0 analysts has given sell rating. The average target price of $6.01 gives the stock implied upside of roughly 92.71% over the next year or so.
Analysts suggest HIVE's stock price would rise to a high of $9.00.
Within the next 12 months, analysts predict the HIVE stock price could move to $3.50.
HIVE stock has an average analyst estimate of $6.01.
HIVE shares are currently trading 92.71% above this price target.
Its quarterly earnings per share (EPS) came in at -$0.06 versus consensus estimates of -$0.09, and above the comparable year-ago quarter’s EPS of -$0.29.
HIVE's forecasts by analysts estimating quarterly EPS at -$0.11 and -$5.49 for the whole year.
The analysts have projected N/A EPS growth for HIVE in the next five years, compared to growth rates of 23.63% in the past five years.